FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average h	nurden							

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fleming Alison B					<u>CC</u>	2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC COLL COLL										neck all a Dir V Off	ationship of Reporti k all applicable) Director Officer (give title below)			son(s) to Iss 10% Ov Other (s below)	ner	
(Last) (First) (Middle) C/O COLLEGIUM PHARMACEUTICAL, INC. 780 DEDHAM STREET, SUITE 800				NC.	04/	3. Date of Earliest Transaction (Month/Day/Year) 04/02/2018											Chi		nology Officer			
(Street)	N M	A	02021		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Lin	e) <mark>X</mark> Fo Fo					on	
(City)	(S		(Zip)																			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D			action	ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		<u>,</u>	3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				5. Ai Secu Bend Own	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
										Code	v	Amount		(A) or (D)	Price	Tran	sact	ion(s) and 4)			(Instr. 4)	
Common Stock (04/02	2/2018	3				M		4,22	5	A \$		8	53,54			D			
Common Stock 04			04/02	2/2018					M		3,91	7 A		\$0.2	8 57,		,458		D			
		Т	able II -									sed of onverti				/ Owne	ed					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Year				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Security			9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Da Ex	ate xercisable		opiration	Title		Amount or Number of Shares							
Stock option (right to purchase)	\$0.28	04/02/2018			М			4,225		(1)	03	3/05/2024	Com		4,225	\$0		0		D		
Stock option (right to	\$0.28	04/02/2018			M			3,917		(2)	03	3/05/2024	Com		3,917	\$0		0		D		

Explanation of Responses:

Remarks:

/s/ Paul Brannelly as Attorney-In-Fact For Alison B. Fleming

04/04/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1. 4,225} option shares are exercisable. The option, initially representing a right to purchase a total of 15,623 shares, vested and became exercisable in equal installments (rounded up to the nearest whole share of common stock) on a monthly basis over a four-year period commencing on March 5, 2014, subject to the reporting person's continued service with the issuer.

^{2. 3,917} option shares are exercisable. The option, initially representing a right to purchase a total of 14,492 shares, vested and became exercisable over a four-year period commencing on March 5, 2014. Twenty-five percent (25%) of the option vested and became exercisable on March 5, 2015 and the balance vested in equal monthly installments (rounded up to the nearest whole share of common stock) at the end of each monthly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer.